Rury R Holman

List of Publications by Year
in descending order

147 papers	29,661 citations	41344 49 h-index	8396 147 g-index
151 all docs	151 docs citations	151 times ranked	20300 citing authors

#	Article	IF	Citations
1	Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. Diabetes Care, 2022, 45, 204-212.	8.6	25
2	Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial. Diabetes Research and Clinical Practice, 2022, 183, 109152.	2.8	2
3	A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk. Science Translational Medicine, 2022, 14, eabj9625.	12.4	31
4	Effect of Fenofibrate Therapy on Laser Treatment for Diabetic Retinopathy: A Meta-Analysis of Randomized Controlled Trials. Diabetes Care, 2022, 45, e1-e2.	8.6	6
5	Validation of the WATCHâ€ĐM and TRSâ€HF _{DM} Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis. Journal of the American Heart Association, 2022, 11, .	3.7	10
6	Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Cardiovascular Diabetology, 2022, 21, .	6.8	3
7	Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension. Annals of Internal Medicine, 2021, 174, 58-68.	3.9	47
8	Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the <scp>EXSCEL</scp> and <scp>SAVORâ€TIMI</scp> 53 cardiovascular outcomes trials. Diabetes, Obesity and Metabolism, 2021, 23, 1101-1110.	4.4	4
9	Predicting the risk of developing type 2 diabetes in Chinese people who have coronary heart disease and impaired glucose tolerance. Journal of Diabetes, 2021, 13, 817-826.	1.8	2
10	Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. Diabetic Medicine, 2021, 38, e14552.	2.3	5
11	Neck circumference and waist circumference associated with cardiovascular events in type 2 diabetes (Beijing Community Diabetes Study 23). Scientific Reports, 2021, 11, 9491.	3.3	7
12	Design and rationale of the EMPAâ€VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure. ESC Heart Failure, 2021, 8, 2580-2590.	3.1	18
13	Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89. Diabetes Care, 2021, 44, 1877-1884.	8.6	25
14	Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. Diabetes Care, 2021, 44, 2231-2237.	8.6	51
15	Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90). Diabetic Medicine, 2021, 38, e14656.	2.3	10
16	Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus. American Heart Journal, 2021, 239, 59-63.	2.7	4
17	Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial. Atherosclerosis, 2021, 338, 1-6.	0.8	6
18	Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS. American Heart Journal, 2020, 219, 47-57.	2.7	45

#	Article	IF	Citations
19	Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes Care, 2020, 43, 374-381.	8.6	4
20	Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. Diabetes, Obesity and Metabolism, 2020, 22, 798-806.	4.4	11
21	Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. Diabetes Care, 2020, 43, 643-652.	8.6	38
22	Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS. American Heart Journal, 2020, 220, 82-88.	2.7	3
23	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. Diabetes Care, 2020, 43, 446-452.	8.6	63
24	Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on postâ€meal glucose excursions and glucagon in type 1 diabetes patients. Endocrinology, Diabetes and Metabolism, 2020, 3, e00130.	2.4	2
25	The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet, The, 2020, 396, 2019-2082.	13.7	327
26	Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans. Nature Communications, 2020, 11, 3766.	12.8	43
27	Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study. Diabetes Care, 2020, 43, 2493-2499.	8.6	29
28	Long-term glucose variability and risk of nephropathy complication in UKPDS, ACCORD and VADT trials. Diabetologia, 2020, 63, 2482-2485.	6.3	14
29	Effect of onceâ€weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the <scp>EXSCEL</scp> trial. Diabetes, Obesity and Metabolism, 2020, 22, 2493-2498.	4.4	26
30	Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data. Diabetes Care, 2020, 43, 2485-2492.	8.6	3
31	Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2ÂÃ— 2ÂÃ— 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning. Value in Health, 2020, 23, 1340-1348.	0.3	3
32	Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial. Diabetes Research and Clinical Practice, 2020, 170, 108488.	2.8	4
33	Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data. Medical Decision Making, 2020, 40, 460-473.	2.4	15
34	Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. Circulation, 2020, 141, 1360-1370.	1.6	9
35	Can the cardiovascular risk reductions observed with empagliflozin in the EMPAâ€REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?. Diabetes, Obesity and Metabolism, 2020, 22, 1151-1156.	4.4	8
36	Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial. Diabetes Care, 2020, 43, 2242-2247.	8.6	11

#	Article	IF	Citations
37	Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the <scp>TECOS</scp> randomized clinical trial. European Journal of Heart Failure, 2020, 22, 2026-2034.	7.1	18
38	Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86). Lancet Diabetes and Endocrinology,the, 2020, 8, 206-215.	11.4	36
39	Improved Framingham Risk Scores of Patients with Type 2 Diabetes Mellitus in the Beijing Community: A 10-Year Prospective Study of the Effects of Multifactorial Interventions on Cardiovascular Risk Factors (The Beijing Communities Diabetes Study 22). Diabetes Therapy, 2020, 11, 885-903.	2.5	5
40	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus. Circulation, 2020, 141, 843-862.	1.6	62
41	Î²-cell secretory dysfunction: a key cause of type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2020, 8, 370.	11.4	21
42	Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Research and Care, 2020, 8, e001238.	2.8	43
43	TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylureaâ€"a MASTERMIND study protocol. BMJ Open, 2020, 10, e042784.	1.9	17
44	Abstract MP36: Effects Of Intensive Blood Pressure Treatment On Orthostatic Hypotension: An Individual-level Meta-analysis. Hypertension, 2020, 76, .	2.7	1
45	Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II). Cardiovascular Diabetology, 2020, 19, 164.	6.8	90
46	Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes. Cardiovascular Diabetology, 2019, 18, 135.	6.8	17
47	Associations between Î²-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease. American Heart Journal, 2019, 218, 92-99.	2.7	4
48	Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Cardiovascular Diabetology, 2019, 18, 138.	6.8	48
49	Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS. Cardiovascular Diabetology, 2019, 18, 116.	6.8	14
50	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. American Heart Journal, 2019, 218, 57-65.	2.7	4
51	Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failureâ€"Related Outcomes. Circulation, 2019, 140, 1613-1622.	1.6	58
52	Comment on Kim et al. The Effect of a Smartphone-Based, Patient-Centered Diabetes Care System in Patients With Type 2 Diabetes: A Randomized, Controlled Trial for 24 Weeks. Diabetes Care 2019;42:3â€"9. Diabetes Care, 2019, 42, e125-e125.	8.6	1
53	Comment on Davis et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. Diabetes Care 2019;42:157â€"163. Diabetes Care, 2019, 42, e95-e95.	8.6	0
54	Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. International Journal of Cardiology, 2019, 289, 58-62.	1.7	2

#	Article	IF	Citations
55	Longâ€term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85). Diabetes, Obesity and Metabolism, 2019, 21, 2115-2122.	4.4	27
56	Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes Care, 2019, 42, 1075-1080.	8.6	15
57	Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010â€“2017. Diabetes, Obesity and Metabolism, 2019, 21, 1576-1584.	4.4	64
58	An outcome model approach to transporting a randomized controlled trial results to a target population. Journal of the American Medical Informatics Association: JAMIA, 2019, 26, 429-437.	4.4	7
59	Progression of glucoseâ€lowering diabetes therapy in TECOS. Endocrinology, Diabetes and Metabolism, 2019, 2, e00053.	2.4	7
60	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. Circulation: Cardiovascular Interventions, 2019, 12, e008018.	3.9	25
61	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. Circulation, 2019, 139, 863-873.	1.6	18
62	Real-world studies no substitute for RCTs in establishing efficacy. Lancet, The, 2019, 393, 210-211.	13.7	78
63	Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. Diabetes Care, 2019, 42, 318-326.	8.6	23
64	Simulating the impact of targeting lower systolic blood pressure and LDL-cholesterol levels on type 2 diabetes complication rates. Journal of Diabetes and Its Complications, 2019, 33, 69-74.	2.3	3
65	Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care, 2018, 41, 705-712.	8.6	67
66	Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes, Obesity and Metabolism, 2018, 20, 1427-1434.	4.4	23
67	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditorsâ€™ Expert Forum. Diabetes Care, 2018, 41, 14-31.	8.6	338
68	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. Diabetes Care, 2018, 41, 596-603.	8.6	59
69	Clinically relevant results from cardiovascular outcome trials. Nature Reviews Endocrinology, 2018, 14, 67-68.	9.6	1
70	Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes and Endocrinology,the, 2018, 6, 105-113.	11.4	451
71	Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes, Obesity and Metabolism, 2018, 20, 1732-1739.	4.4	5
72	Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. American Heart Journal, 2018, 199, 170-175.	2.7	5

#	Article	IF	Citations
73	Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease. Circulation, 2018, 138, 2576-2578.	1.6	13
74	Effect of Onceâ€Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial. Journal of the American Heart Association, 2018, 7, e009304.	3.7	19
75	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, The, 2018, 392, 1519-1529.	13.7	1,179
76	Aspects of Multicomponent Integrated Care Promote Sustained Improvement in Surrogate Clinical Outcomes: A Systematic Review and Meta-analysis. Diabetes Care, 2018, 41, 1312-1320.	8.6	81
77	A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks. Diabetes Care, 2018, 41, 1121-1124.	8.6	43
78	What does the Acarbose Cardiovascular Evaluation (ACE) trial tell us?. Journal of Diabetes, 2018, 10, 683-685.	1.8	4
79	Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. Diabetes, Obesity and Metabolism, 2018, 20, 2379-2388.	4.4	29
80	Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. Diabetes Care, 2018, 41, 1844-1853.	8.6	91
81	Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes, 2018, 67, .	0.6	42
82	Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. Health Technology Assessment, 2018, 22, 1-64.	2.8	28
83	International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial. Journal of the American Heart Association, 2017, 6, .	3.7	4
84	Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Care, 2017, 40, 494-501.	8.6	50
85	Updated risk factors should be used to predict development of diabetes. Journal of Diabetes and Its Complications, 2017, 31, 859-863.	2.3	5
86	Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. Diabetes, Obesity and Metabolism, 2017, 19, 1587-1593.	4.4	24
87	Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus. Circulation, 2017, 136, 1193-1203.	1.6	47
88	Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes and Endocrinology,the, 2017, 5, 431-437.	11.4	379
89	Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). American Heart Journal, 2017, 187, 1-9.	2.7	49
90	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. Diabetes Care, 2017, 40, 1763-1770.	8.6	60

#	Article	IF	Citations
91	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events. Hypertension, 2017, 70, 907-914.	2.7	12
92	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 877-886.	11.4	245
93	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 1228-1239.	27.0	1,455
94	Microvascular outcomes in type 2 diabetes â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2017, 5, 580.	11.4	0
95	Health selection into neighborhoods among patients enrolled in a clinical trial. Preventive Medicine Reports, 2017, 8, 51-54.	1.8	3
96	Sustained influence of metformin therapy on circulating glucagonâ€like peptideâ€1 levels in individuals with and without type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 356-363.	4.4	47
97	Sitagliptin and risk of fractures in type 2 diabetes: <scp>R</scp>esults from the <scp>TECOS</scp> trial. Diabetes, Obesity and Metabolism, 2017, 19, 78-86.	4.4	52
98	Pancreatic Safety of Sitagliptin in the TECOS Study. Diabetes Care, 2017, 40, 164-170.	8.6	49
99	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus. JAMA Cardiology, 2016, 1, 126.	6.1	196
100	The effect of a brief action planning intervention on adherence to double-blind study medication, compared to a standard trial protocol, in the Atorvastatin in Factorial with Omega EE90 Risk Reduction in Diabetes (AFORRD) clinical trial: A cluster randomised sub-study. Diabetes Research and Clinical Practice, 2016, 120, 56-64.	2.8	12
101	Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nature Genetics, 2016, 48, 1055-1059.	21.4	165
102	Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care, 2016, 39, 2304-2310.	8.6	142
103	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. American Heart Journal, 2016, 174, 103-110.	2.7	82
104	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2015, 373, 232-242.	27.0	2,188
105	The effect of glibenclamide on insulin secretion at normal glucose concentrations. Diabetologia, 2015, 58, 43-49.	6.3	13
106	Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2014, 2, 116-124.	11.4	157
107	First-time heart failure increases risk of diabetes mellitus. Nature Reviews Endocrinology, 2014, 10, 453-454.	9.6	1
108	Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetesâ€“Authors' reply. Lancet, The, 2014, 384, 1097-1098.	13.7	4

#	Article	IF	Citations
109	Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. American Heart Journal, 2014, 168, 23-29.e2.	2.7	50
110	Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes and Endocrinology,the, 2014, 2, 843-851.	11.4	260
111	Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet, The, 2014, 383, 2008-2017.	13.7	194
112	Temporal Validation of the UKPDS Outcomes Model Using 10-Year Posttrial Monitoring Data. Diabetes Care, 2013, 36, 1541-1546.	8.6	21
113	Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. American Heart Journal, 2013, 166, 983-989.e7.	2.7	116
114	A Novel Risk Classification Paradigm for Patients With Impaired Glucose Tolerance and High Cardiovascular Risk. American Journal of Cardiology, 2013, 112, 231-237.	1.6	5
115	Optimal management of T2DM remains elusive. Nature Reviews Endocrinology, 2013, 9, 67-68.	9.6	34
116	Prognostic Significance of Silent Myocardial Infarction in Newly Diagnosed Type 2 Diabetes Mellitus. Circulation, 2013, 127, 980-987.	1.6	99
117	Evaluation of a Self-Administered Oral Glucose Tolerance Test. Diabetes Care, 2013, 36, 1483-1488.	8.6	14
118	Predictors of Stroke in Patients With Impaired Glucose Tolerance. Stroke, 2013, 44, 2590-2593.	2.0	8
119	Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. BMJ Open, 2012, 2, e001925.	1.9	23
120	Addition of exenatide to insulin therapy in individuals with type 2 diabetes in UK routine clinical practice. Practical Diabetes, 2012, 29, 61-64.	0.3	1
121	Understanding the outcomes of multi-centre clinical trials: A qualitative study of health professional experiences and views. Social Science and Medicine, 2012, 74, 574-581.	3.8	35
122	Challenges of maintaining research protocol fidelity in a clinical care setting: A qualitative study of the experiences and views of patients and staff participating in a randomized controlled trial. Trials, 2011, 12, 108.	1.6	26
123	Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1032-1040.	4.5	64
124	Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. New England Journal of Medicine, 2010, 362, 1477-1490.	27.0	588
125	Initiating Insulin as Part of the Treating To Target in Type 2 Diabetes (4-T) Trial: An interview study of patients' and health professionals' experiences. Diabetes Care, 2010, 33, 2178-2180.	8.6	27
126	Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events. New England Journal of Medicine, 2010, 362, 1463-1476.	27.0	430

#	Article	IF	Citations
127	Baseline Characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial Population: Comparison with Other Diabetes Prevention Trials. Cardiovascular Therapeutics, 2010, 28, 124-132.	2.5	10
128	Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet, The, 2010, 375, 1365-1374.	13.7	228
129	Perceptions of heart attack risk amongst individuals with diabetes. Primary Care Diabetes, 2009, 3, 239-244.	1.8	6
130	Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. New England Journal of Medicine, 2009, 361, 1736-1747.	27.0	608
131	Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. Diabetes Care, 2009, 32, 193-203.	8.6	2,988
132	Presenting the results of clinical trials to participants. Clinical Medicine, 2009, 9, 415-416.	1.9	4
133	10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine, 2008, 359, 1577-1589.	27.0	6,543
134	Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. American Heart Journal, 2008, 156, 623-632.	2.7	84
135	Determining the most appropriate components for a composite clinical trial outcome. American Heart Journal, 2008, 156, 633-640.	2.7	38
136	Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes. New England Journal of Medicine, 2008, 359, 1565-1576.	27.0	674
137	Rosiglitazone-Associated Fractures in Type 2 Diabetes. Diabetes Care, 2008, 31, 845-851.	8.6	498
138	Framingham, SCORE, and DECODE Risk Equations Do Not Provide Reliable Cardiovascular Risk Estimates in Type 2 Diabetes. Diabetes Care, 2007, 30, 1292-1293.	8.6	158
139	Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. New England Journal of Medicine, 2007, 357, 1716-1730.	27.0	651
140	Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. New England Journal of Medicine, 2006, 355, 2427-2443.	27.0	2,714
141	Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2006, 29, 1963-1972.	8.6	1,089
142	Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. American Heart Journal, 2006, 152, 27-38.	2.7	413
143	Non-HDL Cholesterol Is Less Informative Than the Total-to-HDL Cholesterol Ratio in Predicting Cardiovascular Risk in Type 2 Diabetes. Diabetes Care, 2005, 28, 1796-1797.	8.6	48
144	Sulfonylurea Inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care, 2002, 25, 330-336.	8.6	534

#	Article	IF	Citations
145	Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom Prospective Diabetes Study (UKPDS 47). American Heart Journal, 1999, 138, S353-S359.	2.7	77
146	UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet, The, 1997, 350, 1288-1293.	13.7	704
147	The UK Prospective Diabetes Study. Annals of Medicine, 1996, 28, 439-444.	3.8	39